Home
overview

SMi presents Europe's leading 14th annual Parallel Trade conference, taking place in London on the 4th-5th of February 2020. As the only  B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The size of the EU market in pharmaceutical distribution is around €5bn, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn, while the annual export figure approximates £600m.

The 2020 event will hold a particular place of significance on shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights.

Furthermore, this conference will give companies affected the perfect opportunity to discuss and consider the impact of the FMD (Falsified Medicines Directive) implementation on their practices and on the market.

 


 

• Assessing how EU membership has a “profound effect” on pharmaceutical intellectual property (IP) rights
• What’s the impact and consequences of potentially a no deal Brexit on testing and clinical trials?
• Impact on availability, accessibility and innovation
• Reviewing the market exclusivity of Orphan Drugs and the increasing use of the orphan designation
• Assessing current EU legislative instruments and changes in IP framework
• An update on current illegal trade cases and the Falsified Medicines Directive
• Assessing the EU Regulation 2019/933 which entered into force on 1st July 2019
 

Vice President/ Heads of/General Managers:
• International Trade and Relations
• Supply Chain Development – Brexit
• Brexit Implementation
• Market Access
• Supply Chain Manager
• Parallel trade reporting
• Regulatory Affairs
• IP
• Purchasing
• Policy Patent Operations
• European Affairs
• Supply and Demand
• Attorney
• Distribution 

Companies that attended previously;

AA Thornton ABACUS MEDICINE A/S Abbott Laboratories AbbVie Turkiye AIFA AlixPartners ALK-Abello Allergan Ltd Almirall Amgen Apotek Hjärtat AB Arnold and Porter AstraZeneca Baker & Mckenzie Bayer Biogen International GmbH Boehringer Ingelheim Bristol Myers Squibb British Association of European Pharmaceutical Distributors Celegene Clinical Insights Compelo Group Concordia, International Rx Ltd Covington & Burling DOZ S.A. Dr. Falk Pharma GmbH EAEPC Edwards Life Sciences Eisai Europe Ltd Eli Lilly and Company Epilepsy Action Eumedica S.A. Europe Economics European Alliance for Access to Safe Medicines European Association of Euro-Pharmaceutical Companies European Society for Medical Oncology Ferring International Center S.A. Ferring Pharmaceuticals Freshfields Bruckhaus Deringer LLP Gilead Sciences UK & Ireland GMM FARMA S.r.l. Hollister Inc HPRA Intellectual Property Office Ipsen IQVIA Irish Pharmacy Union Kantar Health Key Pharmaceuticals Ltd Kyowa Kirin International plc Leo PharmaLexano Lisman Legal Life sciences B.V. MD Pharma SA Medac GmbH Medicines for Europe MHRA MP PHARMA SA Mundipharma Mylan Napp Laboratories Narrowcliff Pharmacy Novartis Novo Nordisk Orifarm Generics A/S PAREXEL Pfizer Pharma GmbH PharmaConsult Global Ltd Pharmnet Plus SRL Roche SANOFI Sanofi Genzyme SOTIO a.s. Sunovion Pharmaceuticals Europe Ltd Swiss Pharma International AG Takeda The Economist Intelligence Unit Tillotts Pharma AG UEA, University of East Anglia University of Ferrara and Rome
 

Conference programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Kasper Ernest

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
View Bio

9:10 The political economy of parallel trade

Dermot Glynn

Dermot Glynn, Senior Advisor, Europe Economics
View Bio

  • The law of one price
  • The Justification for patents
  • Efficient pricing for patented products
  • Alternative objectives of competition law
  • Consumer welfare
  • EU integration
  • Squaring the circle
  • Brexit
  •  

    9:50 Regulatory update and overview: Where are we now with Parallel Trade?

    • Reviewing the underlying regulatory structure on parallel trade and how regulation must be recognised and placed on the market in the EU
    • Understanding the relevance of this and depending on the country of focus, what pressures there are on exports of products
    • Gaining clear understanding and interpretation of competition law and how these interactions are made with IP Ascertaining what changes Brexit will have on the ability of manufactures to manage PT
     

    Peter Bogaert

    Peter Bogaert, Managing Partner, Covington & Burling
    View Bio

    Wesley Lepla

    Wesley Lepla, Regulatory Lawyer, Covington & Burling
    View Bio

    10:30 Morning Coffee

    11:00 SPOTLIGHT INTERVIEW

    Morten  Bj Petersen

    Morten Bj Petersen, Owner & Principle Advisor, European Business Advisory
    View Bio

    • What is advocacy in Brussels?
    • What does that mean at the British Chamber?
    • What could Brexit look like – before, during and after?
    • What is the importance of business operators to be present in Brussels?
     

    11:40 Parallel trade and availability of medicines

    John Lisman

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    View Bio

  • Analysis of the causes of medicine shortages
  • Regulatory activity in solving the problem of shortages
  • Role of parallel trade in causing and solving shortages


  •  

    12:20 Networking Lunch

    13:20 Exploring and understanding the exhaustion of IP rights

    Aleksandra Bzdzikot

    Aleksandra Bzdzikot, IP Lawyer, Independent
    View Bio

    • How is the concept of national, regional or international exhaustion applied?
    • Repackaging issues and trademark infringement. How to balance between these two?
    • Current jurisprudence on parallel import cases in trademark law
     

    14:00 Insight into latest trends of Parallel Trade across EU and main drivers

    Shabnam Hanassab

    Shabnam Hanassab, Engagement Manager, IQVIA
    View Bio

    • Overview on PI sales trends across EU in 2019 compared to past
    • Glance on latest main drivers of PI sales, Brexit and German new legislations
    • Updates on other drivers
     

    14:40 Afternoon Tea

    15:10 PANEL DISCUSSION

    • Underlying principles of the EU Internal market and Competition policies
    • What lies behind the EU fundamental thinking of institutions as drivers for trade, competition and the EU market?
    • What is the policy, legal and motivational drivers?
     

    John Lisman

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    View Bio

    Morten  Bj Petersen

    Morten Bj Petersen, Owner & Principle Advisor, European Business Advisory
    View Bio

    Werner Berg

    Werner Berg, Partner, Baker Mckenzie
    View Bio

    Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

    Richard  Freudenberg

    Richard Freudenberg, President - Chief Executive, BAEPD
    View Bio

    16:10 Competition Law - An update

    Werner Berg

    Werner Berg, Partner, Baker Mckenzie
    View Bio

    • What are the procedures that have been taken on by the European Commission and National Authorities?
    • Assessing the developments and landscape on risk and investigations
    • What are the developments on a national level?
    • Exploring the outlook and looking forward
     

    16:50 Chair’s Closing Remarks and Close of Day One

    Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

    8:30 Registration & Coffee

    9:00 Chair's Opening Remarks

    Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

    9:10 Assessing the current situation, impact and consequences of Parallel Trade?

    David Guest

    David Guest, Manager, Parallel Import Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
    View Bio

    Session Reserved

    9:50 The impact of parallel trade in patient safety

    10:30 Morning Coffee

    11:00 DEEP DIVE SHORTAGES PANEL DISCUSSION: The impact on patient safety

    • Parallel trade management to ensure patient safety
    • Continuing to deliver to patients in the UK
    • The creation of shortages through the parallel export of medicines from states with lower costing medicines
    • Would there be any way to change the market dynamic to reduce the level of shortages
    • Discussing the hurdles surrounding Competition law
     

    Nick Kaye

    Nick Kaye, Superintendent Pharmacist , Narrowcliff Pharmacy
    View Bio

    Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

    John Lisman

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    View Bio

    Richard  Freudenberg

    Richard Freudenberg, President - Chief Executive, BAEPD
    View Bio

    11:40 Open Discussion

    Christopher Stothers

    Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP
    View Bio

    This session will be chaired by Christopher, who will set the scene before breaking out into group discussion on the key topics below, with twenty minutes per bullet point to allow some fruitful and open discussions amongst the groups:
    • What are the significant medium- and long-term impact for UK intellectual property rights and exhaustion?
    • Will the transitional regime(s) provide continuity in the UK and in the EU?
    • How may UK IP law diverge from the EU over time?
     

    12:30 Networking Lunch

    13:30 SPOTLIGHT

    Elizabeth Pisani

    Elizabeth Pisani, Associate Professor, School of Health Policy and Management , Erasmus University
    View Bio


     

    14:10 Out of Industry Case Study: Mitsubishi

    Jeremy Blum

    Jeremy Blum, Partner, Bristows
    View Bio

    • Infringing and interfering with trademarks
    • The implications of entire removal of brand from the product
    • The challenges, hurdles and implications in the Mitsubishi case study and how this can be applied to pharma
     

    14:50 Afternoon Tea

    15:20 Insights into Eastern Europe (EE)

    Martin Slegl

    Martin Slegl, Regional Principal of East Europe, IQVIA
    View Bio

    • Updates about distribution legal changes across EE
    • Availability of specialty drugs in EE
    • EE as import market(s)
     

    16:00 Product Proliferation: Entry deterrence, market shares and growth

    Farasat Bokhari

    Farasat Bokhari, Associate Professor, UEA, University of East Anglia
    View Bio

    This talk will focus on strategic and non-strategic reasons for introducing additional drugs by a monopolist near the end of market exclusivity period for the original drug.
    • Are these drugs introduced to deter generic entry, and if so, is it an effective strategy?
    • Similarly, post entry, do additional product and pack variations by an incumbent help with revenue growth of the business unit?
    • Questions will be analysed using sales and entry data from the UK market
     

    16:40 Chair’s Closing Remarks and Close of Day Two

    Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

    Richard  Freudenberg

    Richard Freudenberg, President - Chief Executive, BAEPD
    View Bio

    Richard  Freudenberg

    Richard Freudenberg, President - Chief Executive, BAEPD
    View Bio

    +

    FEATURED SPEAKERS

    Aleksandra Bzdzikot

    Aleksandra Bzdzikot

    IP Lawyer, Independent
    Christopher Stothers

    Christopher Stothers

    Partner, Freshfields Bruckhaus Deringer LLP
    David Guest

    David Guest

    Manager, Parallel Import Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
    Dermot Glynn

    Dermot Glynn

    Senior Advisor, Europe Economics
    Elizabeth Pisani

    Elizabeth Pisani

    Associate Professor, School of Health Policy and Management , Erasmus University
    Farasat Bokhari

    Farasat Bokhari

    Associate Professor, UEA, University of East Anglia
    Jeremy Blum

    Jeremy Blum

    Partner, Bristows
    John Lisman

    John Lisman

    Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    Martin Slegl

    Martin Slegl

    Regional Principal of East Europe, IQVIA
    Morten  Bj Petersen

    Morten Bj Petersen

    Owner & Principle Advisor, European Business Advisory
    Nick Kaye

    Nick Kaye

    Superintendent Pharmacist , Narrowcliff Pharmacy
    Peter Bogaert

    Peter Bogaert

    Managing Partner, Covington & Burling
    Shabnam Hanassab

    Shabnam Hanassab

    Engagement Manager, IQVIA
    Werner Berg

    Werner Berg

    Partner, Baker Mckenzie
    Wesley Lepla

    Wesley Lepla

    Regulatory Lawyer, Covington & Burling

    Aleksandra Bzdzikot

    IP Lawyer, Independent
    Aleksandra Bzdzikot

    Aleksandra Bzdzikot is an independent IP lawyer specialized in parallel import and trademark infringement cases. She gained her experience while working for Swiss Pharma International AG in Switzerland advising the biggest pharma companies in Poland and Russia. Aleksandra can advise on the full range of parallel import questions related to trademark infringement, repackaging of the medicinal products and influence of FMD on parallel traders’ obligations towards trademark owners.

    Christopher Stothers

    Partner, Freshfields Bruckhaus Deringer LLP
    Christopher Stothers

    Christopher is a recognized expert in parallel trade, with a particular focus on the pharmaceutical sector - his 2007 textbook, “Parallel Trade in Europe: Intellectual Property, Competition and Regulatory Law,” has been cited by the UK Supreme Court. Christopher is also an experienced litigator on cross-border patent disputes, other types of intellectual property, antitrust, pharmaceutical regulation, EU law and commercial disputes. He has taken cases before the First Tier Tribunal, the Upper Tribunal, the Patents County Court, the High Court, the Court of Appeal, the House of Lords, the Supreme Court, the European Patent Office, and the European Court of Justice.

    David Guest

    Manager, Parallel Import Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
    David Guest

    After more than 20 years as a Process Development chemist for a major pharmaceutical company, David joined one of the largest UK Parallel Importers as Regulatory Affairs Manager. His 5 year tenure gave him a good understanding of the restrictions and pressures on importers.
    Since joining MHRA as Manager of the Parallel Import Unit this industry experience has been beneficial in guiding changes to the internal assessment processes to provide a better service to industry while ensuring an appropriate focus on patient safety.
     

    Dermot Glynn

    Senior Advisor, Europe Economics
    Dermot Glynn

    Dermot Glynn is Senior Advisor to and founder of Europe Economics.

    His areas of expertise include economic regulation, competition policy, and public policy evaluation. He has worked extensively in the utility sectors, directing consultancy projects and providing expert advice to both regulators and regulated businesses. He has led numerous seminars on regulatory issues and on the concepts and techniques of impact assessment of public policies, and advised the National Audit Office (NAO) in its technical review of impact assessments carried out by UK Government Departments and agencies.

    Before founding Europe Economics Dermot Glynn served as Economic Director of the Confederation of British Industry (CBI), Chief Economist at KPMG, and UK Managing Director of NERA. He read Politics, Philosophy and Economics at Balliol College, Oxford, and was a member of the Department of Applied Economics at Cambridge University.

    Elizabeth Pisani

    Associate Professor, School of Health Policy and Management , Erasmus University
    Elizabeth Pisani

    Elizabeth is an epidemiologist focusing on the intersection between public health evidence and the messy realities of politics, culture and money. She is currently leading research that uses economic and market indicators to predict the risk of substandard and falsified medicines in national supply chains. Elizabeth is an Associate Professor at Erasmus School of Health Policy and Management in Rotterdam, and holds honorary posts at London School of Hygiene and Tropical Medicine, the Policy Institute at King's College London and the George Institute for Global Health. She holds a PhD in Infectious Disease Epidemiology and an MSc in Medical Demography (both from LSHTM) and, absurdly, an MA in Classical Chinese from Oxford.

    Farasat Bokhari

    Associate Professor, UEA, University of East Anglia
    Farasat Bokhari

    Farasat Bokhari is a Senior Lecturer (Associate Professor) in the School of Economics and Centre for Competition Policy at the University of East Anglia. He is a health economist with a background in applied microeconomics and industrial organization, with a specialization in health policy. He has conducted research related to impact of public health financing on health outcomes as well as of other regulations on healthcare utilization. Dr. Bokhari’s research extends to competition and antitrust in the healthcare sector. His recent work is on welfare effects of new entrants, particularly of generic and follow-on (`me-too') drugs in the pharmaceutical markets. He has been active in studying firm strategies relating to pricing, launch of authorized generics, conducting pay-for-delay deals, and product differentiation and mergers and their impact on industry performance and structure.

     

    Jeremy Blum

    Partner, Bristows
    Jeremy Blum

    Jeremy is an IP specialist and has advised on many contentious matters involving trade marks, copyright, designs, patents and confidential information. He has a particular focus on trade marks, design and copyright. He has advised on a number of high profile disputes before the High Court, Court of Appeal, Court of Justice, EUIPO and General Court. He has even led the advocacy before the Court of Justice.
    Jeremy has acted in some of the leading cases that have developed intellectual property law such as:
    • L’Oreal v eBay which concerned the liability of online e-commerce platforms and was the first case to consider injunctions against non-infringing intermediaries
    • Cadbury v Nestle which concerned the registrability of the shape of a four-fingered KitKat chocolate bar
    • Glaxo v Sandoz concerning the colour and shape of an asthma inhaler for passing off.
    Jeremy also has extensive registered design, unregistered design and copyright litigation experience for a diverse range of products ranging from luxury jewellery and fashion, plastic containers, artworks, pharmaceutical products and consumer goods.
    In particular Jeremy is a specialist in advising on strategies to combat IP infringement in the digital world and has advised on a number of cases regarding online infringement. As a consequence, Jeremy also has a particular interest in cross border injunctions and jurisdiction for community trade marks and designs as well as copyright.
    As part of his breach of confidential information practice, Jeremy has considerable experience in arbitration and has acted in cases before the LCIA and SCC (Stockholm Chamber of Commerce) as well as ad hoc arbitrations. Jeremy specialises in arbitration involving technical subject matter and his cases have ranged from chemical compounds used in deodorants to chemical processes. Many of his arbitration cases involve substantial damages claims.
    Jeremy also provides advice in relation to European regulatory aspects of food and beverage labelling.

     

    John Lisman

    Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    John Lisman

    John Lisman is trained both as a pharmacist and a lawyer. From 1992 until 2007 he was a policy officer in the Ministry of Health and the Medicines Evaluation Board and represented the Netherlands in the Heads of Agencies meeting and the European Medicines Agency Management Board. In 2007 John changed his course to become a private lawyer, first in the largest law firm in the Benelux, NautaDutilh, and since 2010 in Lisman Legal Life sciences B.V..
    John Lisman is publishing broadly in journals and has published more than 200 annotations in Dutch case law collections. He has presented many papers in the Netherlands and abroad.
     

    Kasper Ernest

    Secretary General, European Association of Euro-Pharmaceutical Companies
    Kasper Ernest

    Kasper Ernest has worked for the last 9 years in European affairs advocacy in Brussels. From 2009 -2018 he was with the Confederation of Danish Enterprise, since 2015 serving as Director of the EU & International Department. He has also served as the Board Member of several EU-level business organisations, as a Member of the Danish Government’s Implementation Council, and was co-founder of the European Business Services Alliance. In addition, he is an external lecturer at Copenhagen Business School. He holds a Master’s degree in International Business and Politics from Copenhagen Business School and Singapore Management University.

    Martin Slegl

    Regional Principal of East Europe, IQVIA
    Martin Slegl

    • Martin has over 9 years experience in the area of management consulting, he was leading South East Europe consulting with IQVIA (10 countries). His current role is General Manager for the Czech Republic and Slovakia
    • His specialty is cross border trade and he has worked for a large number of HQs across Europe in different therapy areas
    • He has proven project experience across a variety of industries through Europe as he worked with Roland Berger and A.T. Kearney
    • Martin holds CEMS Master's in International Management and Master’s in Business Economics degrees from ESADE and University of Economics in Prague
     

    Morten Bj Petersen

    Owner & Principle Advisor, European Business Advisory
    Morten  Bj Petersen

    Morten is an experienced EU Public Policy Consultant specialised in trade policy, with special focus on trade remedy, trade negotiations, customs and other market access related issues. UK’s decision to leave the EU has caught his special attention having accumulated substantial experience and developed a significant Brexit relevant public policy network on both sides.
    Morten worked for the European Commission DG Trade and DG Competition from 2004 to 2009, where after he established his own Brussels consultancy European Business Advisory (“EBA”). In 2012 he joining EPPA, a Brussels based Public Policy Consultancy focusing his practice on helping clients to manage alignment between business, European Union institutions and national governments focusing on creating a lasting constructive dialogue with policy-makers.
    His regulatory practice focus primarily on market access issues englobing trade, competition and single market policy issues. One of his specialities remain Trade Defence Instruments such as Antidumping and Anti-subsidy leading him to advice and represent interested parties before the European Commission and Member States. Morten also advice on trade negotiations and is a lead Brexit advisor and Chair of the Future Relations Committee at the British Chamber of Commerce to the EU | Belgium.
    Morten has extensive experience in EU Policy at political and technical level supporting stakeholders in their dialogue with policy makers, legislators and regulators throughout the three European Institutions and in Member State capitals.
    Prior to engaging in public policy, Morten acquired solid experience for more than 15 years in higher management positions working for European and International companies in industry, services and FMCG sectors.
    During the cause of his career, Morten worked in Denmark, Germany, Switzerland, France and Belgium. He is fluent in Danish, English, French and Swedish, comfortable in German and Italian.
    Morten took his degree in International Business Economics at Copenhagen University.

    Nick Kaye

    Superintendent Pharmacist , Narrowcliff Pharmacy
    Nick Kaye

    Nick Kaye is a third-generation community pharmacist; he qualified from Bradford University in 1998. He worked as pre-registration student in a family run community pharmacy and at St James University Hospital Leeds. Since qualifying he has worked for independent pharmacy and as a locum for CAA and AIM pharmacies. Nick was the Superintendent Pharmacist of Nick Kaye’s Pharmacy in Newquay in Cornwall a role he took on in 2011.Since taking over that role the pharmacy has won several awards including, C&D finalist 2013, Pharmacy Business award winner Entrepreneur 2012 and Alphega pharmacy of the year 2013. Nick is now a co-owner of Hendra’s Pharmacy in Penryn and a Partner in a GP practice group that operates in Camborne and Mevagissey. Nick was elected to NPA board 2014; he is assistance Chief Officer of Cornwall and Isle of Scilly LPC, the Chair of the Peninsula LPF(local practice forum) a member of Peninsula LPF, a delegate on European COST group on Medicines shortages and an ex EPF (European Pharmacist Forum) member. Nick has worked with Pharma on focus groups for Pizfer, HFA, Warner Chillcott. Nick has been a speaker at various Pharmacy events and is media trained and has been a spokesperson for Pharmacy Voice and NPA on local and national Radio including Radio 4 you and yours.

    Peter Bogaert

    Managing Partner, Covington & Burling
    Peter Bogaert

    Peter Bogaert is a managing partner of the Brussels office, and has a broad European life sciences practice. He has detailed regulatory expertise under EU and national laws, handles legislative and other policy assignments and provides strategic advice. He also represents life sciences companies before the European Courts in Luxembourg and in local litigation in Belgium. Mr. Bogaert's practice covers pharmaceuticals, biotechnology, medical devices, special foods and feed, cosmetics and other consumer products and he represents numerous innovative life sciences companies, including start-ups, as well as several industry associations.
    Chambers Global notes that a client said “He is an extremely experienced professional with broad expertise and provides sensible and well-balanced solutions." He is consistently ranked by PLC as one of the leading life sciences lawyers globally and Legal 500 EMEA and Chambers Europe note Mr. Bogaert's prominent regulatory pharmaceutical and environmental practice. Legal 500 EMEA (2011) noted that he is "a superb lawyer who is very pleasant to work with." Mr. Bogaert regularly writes and speaks on life sciences issues. He is a founding member of the Brussels Pharma Law Group.

     

    Richard Freudenberg

    President - Chief Executive, BAEPD
    Richard  Freudenberg

    Richard Freudenberg has worked in the PPDI since 1990, for 15 years as Finance Director and subsequently as Managing Director of founder BAEPD member, Doncaster Pharmaceuticals Group Limited.
    Richard has also been a BAEPD Director and member of the association's managing Council from December 2001, and acceded to the BAEPD secretariat in 2005. He has during this period also been (since 2011) Chief Executive of, and twice President (2007-2008 & 2011 to date) of EAEPC

     

    Shabnam Hanassab

    Engagement Manager, IQVIA
    Shabnam Hanassab

    IQVIA’s expert and thought leader in European Parallel Trade dynamics, supply chain and distribution with several years of experience working in this field. Shabnam has developed in-depth expertise in pharmaceutical market dynamics and the increasing complexities of the trading environment. Shabnam is highly experienced on IQVIA’s data types, coverage and various supply chain offerings available centrally as well as locally, working with network of people within and outside organization. She has led several European supply chain consulting projects in the past few years.
    Shabnam holds BSc, MSc and PhD from University of London in Pharmaceutical and Computational Chemistry.
     

    Tushar Patel

    Principal Consultant, Key Pharmaceuticals Ltd
    Tushar Patel

    Werner Berg

    Partner, Baker Mckenzie
    Werner Berg

    Dr. Werner Berg, LL.M, is a partner in the Antitrust & Competition Practice Group in Baker McKenzie, Brussels. Werner has extensive experience advising in the life sciences/pharmaceuticals and chemical industries. He advises on all aspects of European and German antitrust law. Werner has represented companies in numerous merger cases, counseled and represented companies in abuse of dominance investigations and has conducted more than 20 litigation matters before the European Union courts. He is ranked as a recommended Lawyer in Chambers Global and Chambers Europe, the EMEA Legal 500, Best Lawyers and European Legal Experts and features as Acritas Star since 2018.
    He has written more than 100 articles and contributions to commentaries on competition and EU law, and is the co-editor of Berg/Mäsch, Deutsches und Europäisches Kartellrecht 3rd ed. 2018. Werner teaches competition law at Queen Mary College, University of London, the College of Europe and the University of Trier.
     

    Wesley Lepla

    Regulatory Lawyer, Covington & Burling
    Wesley Lepla

    Wesley Lepla advises on all aspects of Belgian and European competition law, including merger control, cartels, anticompetitive agreements, abuse of a dominant position, and state aid law.
    He has worked on a range of merger control cases before the European Commission and numerous national authorities and has gained extensive experience in coordinating multijurisdictional merger control notifications and proceedings. Mr. Lepla has represented clients in antitrust proceedings and regularly counsels on state aid, vertical agreements, and the licensing of intellectual property rights.
    Mr. Lepla is also a research and teaching assistant at the law faculty of the Free University of Brussels (VUB).
     

    Xavier Muntaner Sitges

    Global Pricing & Contracting Specialist, Almirall S A
    Xavier Muntaner Sitges

    Workshops

    Parallel Trade and Brexit… Where are we now?
    Workshop

    Parallel Trade and Brexit… Where are we now?

    Holiday Inn Kensington Forum
    3rd February 2020
    London, United Kingdom

    Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade
    Workshop

    Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade

    Holiday Inn Kensington Forum
    3rd February 2020
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Parallel Trade Infographic

    Download

    Speaker Interview with Martin Slegl

    Download

    Speaker Bio's for 2020

    Download

    Speaker Interview - John Lisman, Lisman Legal Life sciences B.V.

    Download

    Full Programme

    Download

    Parallel Trade brochure 2020

    Download

    Past Attendees 2018-2019

    Download

    PAST PRESENTATION BY VENEZA YUZON, AMGEN

    Download

    PAST PRESENTATION BY PAUL UPHAM, ROCHE

    Download

    PAST PRESENTATION BY MICHAEL SONG, MEDIMMUNE

    Download

    PAST PRESENTATION BY LARRY ATUPEM, ZEON

    Download

    PAST PRESENTATION BY JOKE MAES, TERUMO, CHRIS FRANZESE AND MOLLY LARSON-WAKEMAN, MATCHSTICK

    Download

    PAST PRESENTATION BY ED ISRAELSKI, CHPF

    Download

    PAST PRESENTATION BY DAVID POST, ABBVIE

    Download

    PAST PRESENTATION BY SHOTA ARAKAWA, MITSUBISHI GAS CHEMICAL

    Download

    PAST PRESENTATION BY URI BARUCH, CAMBRIDGE DESIGN PARTNERSHIP

    Download

    PAST PRESENTATION BY PIERRE GOLDBACH, ROCHE

    Download

    PAST PRESENTATION BY MICHAEL HOOVEN, ENABLE INJECTIONS

    Download

    PAST PRESENTATION BY JOEL RICHARD, IPSEN

    Download

    PAST PRESENTATION BY JAYNE LAWRENCE, THE UNIVERSITY OF MANCHESTER

    Download

    PAST PRESENTATION BY FRANCESCO MALAVASI, NOVARTIS

    Download

    PAST PRESENTATION BY FIE FALCK LARSEN, LEO

    Download

    PAST PRESENTATION BY DR. ANDREW FIORINI, GSK

    Download

    PAST PRESENTATION BY DR. AHMED YOUSSEF, SANOFI

    Download

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out